Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

To be considered for this study, you must be 18 years or older with a confirmed diagnosis of high-grade ovarian, primary peritoneal, or fallopian tube cancer. Your cancer must have returned after one previous course of platinum-based chemotherapy, and critically, it needs to be 'platinum-sensitive.' This means your cancer did not grow back for at least six months after your last platinum-based treatment.

Another important requirement is that your cancer cells must show a certain level of a marker called Folate Receptor Alpha (FRα). This will be checked using a tissue sample from your cancer. If you have a specific genetic change (BRCA mutation), you generally need to have tried a type of drug called a PARP inhibitor unless your doctor says you absolutely cannot take it.

You should generally be feeling well enough to participate, with a good level of physical activity. Any side effects from your previous treatments should have mostly cleared up, and you must have some cancer that can be measured by scans.

If you decide to join this study, you would first undergo several tests to make sure you meet all the criteria, including providing a tissue sample to check for the FRα marker. If eligible, you would start treatment with both mirvetuximab soravtansine and carboplatin. This combination would typically be given for up to six cycles. During this period, you would have regular hospital visits for infusions, blood tests, and scans to monitor your health and how the treatment is working. If the treatment is helping and your cancer isn't getting worse after these six cycles, you would then continue to receive mirvetuximab soravtansine on its own.

Throughout your participation, you would have regular check-ups, which would involve physical examinations, blood tests, and imaging scans (like CT scans) to track your progress and manage any side effects. The total length of your participation would depend on how your body responds to the treatment and whether your cancer stays stable, but it could last for many months as long as the treatment is beneficial and you are tolerating it well.